<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35568194</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-6744</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>American heart journal</Title>
          <ISOAbbreviation>Am Heart J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">S0002-8703(22)00094-1</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2022.05.009</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">B-type natriuretic peptide (BNP) is a risk factor for stroke and cardiac death in patients with atrial fibrillation. We hypothesized the prognostic outcomes of very elderly non-valvular atrial fibrillation (NVAF) patients ineligible for standard anticoagulation treatment would vary according to BNP stratification.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this subanalysis of the ELDERCARE-AF trial, patients were stratified by BNP levels at enrollment, and clinical outcomes compared among BNP subgroups. Hazard ratios were adjusted for age, atrial fibrillation type, body mass index, creatine clearance, congestive heart failure, and D-dimer. BNP levels were measured using chemiluminescence enzyme immunoassays.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 984 patients (average age: 86.6 years) not considered eligible for oral anticoagulant therapy at approved doses for stroke prevention were included. The BNP levels at enrollment were &lt;200 (low), 200 to &lt;400 (moderate), and ≥400 (high) pg/mL in 428, 300, and 256 patients, respectively. The number (%) of patients with stroke or systemic embolism (SSE) was 7 (1.2%), 24 (5.9%), and 28 (8.6%) in the low, moderate, and high BNP subgroups, respectively (adjusted hazard ratio 3.82, P=.0025 for low versus moderate BNP and 4.76, P=.0007 for low versus high BNP). There was no significant difference in major bleeding incidence between the BNP subgroups. Edoxaban 15 mg was associated with a consistent reduction in SSE versus placebo in all BNP subgroups.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Stratification by BNP level was associated with the incidence of SSE for very elderly NVAF patients ineligible for standard anticoagulation treatment, and the effect of edoxaban 15 mg was consistent across BNP levels.</AbstractText>
          <CopyrightInformation>Copyright © 2022. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Okazaki</LastName>
            <ForeName>Osamu</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ookazaki@me.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higashino</LastName>
            <ForeName>Yorihiko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Medical Corporation Aishinkai, Higashi Takarazuka Satoh Hospital, Hyogo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yokoya</LastName>
            <ForeName>Koichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, National Hospital Organization Toyohashi Medical Center, Aichi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>An</LastName>
            <ForeName>Yoshimori</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanizawa</LastName>
            <ForeName>Kimihiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development Department III, Development Function, Research and Development Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imamura</LastName>
            <ForeName>Yuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development Department III, Development Function, Research and Development Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayashi</LastName>
            <ForeName>Takuya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Data Intelligence Group, Data Intelligence Department, Digital Transformation Management Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akao</LastName>
            <ForeName>Masaharu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Okumura</LastName>
            <ForeName>Ken</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamashita</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am Heart J</MedlineTA>
        <NlmUniqueID>0370465</NlmUniqueID>
        <ISSNLinking>0002-8703</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">B-type natriuretic peptide</Keyword>
        <Keyword MajorTopicYN="N">ELDERCARE-AF</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
      </KeywordList>
      <CoiStatement>Author disclosures Osamu Okazaki, Yorihiko Higashino and Koichi Yokoya have received grants from Daiichi Sankyo. Yoshimori An has received grants and lecture fees from Daiichi Sankyo. Kimihiko Tanizawa, Yuki Imamura, and Takuya Hayashi are employees of Daiichi Sankyo. Masaharu Akao has received lecture fees from Bristol-Myers Squibb and Boehringer Ingelheim and grant support and lecture fees from Bayer Healthcare and Daiichi Sankyo. Ken Okumura has received lecture fees from Daiichi Sankyo, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Johnson &amp; Johnson, and Bayer. Takeshi Yamashita has received grant support and lecture fees from Daiichi Sankyo, Bristol-Myers Squibb, and Bayer; lecture fees from Pfizer, Nippon Boehringer Ingelheim, and Ono Pharmaceutical; advisory fees from Toa Eiyo; and lecture fees and advisory fees from Novartis. No other potential conflict of interest relevant to this article was reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>19</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35568194</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ahj.2022.05.009</ArticleId>
        <ArticleId IdType="pii">S0002-8703(22)00094-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
